Key result
Cardiac myosin autoantibodies from patients with dilated cardiomyopathy caused greater inhibition of myocyte contraction compared to antibodies from ischemic heart disease patients (P=0.004).
Why the study?
Do human cardiac myosin autoantibodies from patients with dilated cardiomyopathy impair myocyte contractility in isolated rat ventricular myocytes?
Do human cardiac myosin autoantibodies from patients with dilated cardiomyopathy impair myocyte contractility in isolated rat ventricular myocytes?
p-value: p=0.004
Cardiac myosin autoantibodies from patients with dilated cardiomyopathy directly impair myocyte contractility and alter calcium handling, suggesting a pathogenic role in clinical DCM.
No takes yet. Share an insight, caveat, or question.
Supports pathogenic autoantibodies in DCM; hypothesis-generating from animal data and should not change practice.
Warraich et al. (2006) studied Dilated cardiomyopathy and ischemic heart disease (n=38). Cardiac myosin autoantibodies from DCM patients vs. Cardiac myosin autoantibodies from IHD patients was evaluated on Inhibition of contraction in isolated myocytes (p=0.004). Cardiac myosin autoantibodies from patients with dilated cardiomyopathy caused greater inhibition of myocyte contraction compared to antibodies from ischemic heart disease patients (P=0.004).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: